IA
AXSM icon

Integrity Alliance’s Axsome Therapeutics AXSM Stock Holding History

Integrity Alliance’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Sell
9,585
-20
-0.2% -$3.46K 0.06% 231
2025
Q4 		$1.75M Buy
+9,605
New +$1.34M 0.06% 230

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integrity Alliance's AXSM Position: Q1 2026 in Review

Integrity Alliance reduced its Axsome Therapeutics (AXSM) stake by 0.21% in Q1 2026, selling an estimated $3.46K and leaving 9,585 shares worth $1.62M. The position accounts for 0.06% of the portfolio, ranked #231.

Integrity Alliance first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.75M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Integrity Alliance held 9,585 shares of Axsome Therapeutics worth $1.62M as of Q1 2026.
  • Integrity Alliance sold 20 Axsome Therapeutics shares in Q1 2026, an estimated $3.46K.
  • Axsome Therapeutics made up 0.06% of Integrity Alliance's portfolio in Q1 2026, its #231 holding.
  • Integrity Alliance first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Integrity Alliance's Axsome Therapeutics position peaked at $1.75M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Integrity Alliance's 13F filing for Q1 2026, filed 11 May 2026.